VAXDIAX is a brand of BacTrace BioTec AG
VAXDIAX
The rapid test for the detection of antibodiesafter COVID-19 vaccinations.
VAXDIAX is a brand of BacTrace BioTec AG
VAXDIAX
The rapid test for the detection of antibodies after COVID-19 vaccinations.
The VAXDIAX antibody test after COVID-19 vaccinations has been developed to detect the status of highly specific neutralizing antibodies against SARS-CoV-2.
The test, which is CE-marked and manufactured in Germany, provides a test result in 5-10 minutes, depending on the titer strength, based on the WHO reference value for analytical sensitivity of 35 BAU/ml.
Partnerships
BacTrace BioTec AG works closely with a renowned and decorated Scientific Advisory Board as well as with internationally recognized universities and scientific institutions.
- Prof. Dr. Dr. h.c. mult. Willi Jäger, Universität Heidelberg
- Dipl.-Ing. Manfred Opel, Brigade General a.D.
- Prof. Dr. Valentin N. Pavlov, Bashkir State Medical University
- Priv.-Doz. Dr. med. Michael T. Pawlik, Universität Regensburg
- Dr. med. Sören Wagner, Harvard Medical School
- Prof. Dr. med. Dr. h.c. mult. Wolf F. Wieland, Universität Regensburg
- Dr. med. Hans Hermann Wörl
-
BacTrace BioTec AG
Autharistrasse 31
81545 Munich
Germany
- General Information
- info@bactrace.de
- +49 (0) 89 540 464-13
- Sales and Marketing
- sales@bactrace.de
- +49 (0) 89 540 464-13
- Public Relations
- press@bactrace.de
- +49 (0) 89 540 464-13